Aduro BioTech, Inc. (ADRO)

References herein to “we,” “us,” “Company”, and “Aduro” refer to Aduro Biotech,
Inc. and its consolidated subsidiaries unless the context specifically states

We are an immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of challenging
diseases, including cancer. We believe our three technology platforms are
uniquely positioned to recruit and direct the immune system by activating
cancer-fighting immune cells and inhibiting immune suppressive cells known to
allow tumor growth. Product candidates from our STING Pathway Activator,
B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted
Listeria monocytogenes platforms are designed to stimulate and/or regulate
innate and adaptive immune responses, either as single agents or in combination
with conventional therapies (i.e. chemotherapy and radiation) as well as other
novel immunotherapies.  

Leave a Reply

Your email address will not be published. Required fields are marked *